Chronic Obstructive Pulmonary Disease (COPD)

Definition

• Emphysema - destruction of alveolar walls and elastic support
• Chronic Bronchitis - persistent productive cough for at least 3 months per year in 2 consecutive years

COPD is the 3rd most common cause of death in the United States, accounting for over $40 billion per year in direct and indirect healthcare costs. (Katzung's Basic and Clinical Pharmacology)

Etiology & Risk Factors

Pathophysiology

Emphysema

• Enlargement of air spaces distal to terminal bronchioles from destruction of alveolar elastic support
• Proteases (mainly from neutrophils) destroy elastin - in normal lungs, α1-antitrypsin inhibits these proteases
• Two subtypes:
  • Centriacinar (centrilobular) - most common; smoking-related; upper lobe predominance
  • Panacinar - associated with α1-antitrypsin deficiency; lower lobe predominance
• Results in: increased lung compliance, static and dynamic lung hyperinflation, increased chest volume ("barrel chest"), dyspnea
• Blood gases: relatively preserved oxygenation at rest ("pink puffer")

Chronic Bronchitis

• Mucus hypersecretion in proximal airways due to surface epithelial mucous metaplasia and submucosal gland expansion
• Combined with ciliary dysfunction - impaired mucociliary clearance
• Small airway mucus occlusion correlates with severity of airflow obstruction
• Histology: enlarged mucus-secreting glands, goblet cell metaplasia, inflammation, bronchiolar wall fibrosis
• Blood gases: hypoxemia and hypercapnia ("blue bloater")
• MUC5AC concentration increased 10-fold and MUC5B 3-fold in severe COPD

Airflow Limitation & Exercise Intolerance

1. Decreased ventilatory capacity - increased airway resistance + reduced lung elastic recoil
2. Increased ventilatory requirement - V/Q mismatch
3. Dynamic hyperinflation - during exercise, end-expiratory lung volume (EELV) rises, inspiratory reserve volume (IRV) falls, causing "neuromechanical uncoupling" and severe dyspnea
4. Cor pulmonale (right-sided heart failure) in advanced disease from chronic hypoxic pulmonary vasoconstriction

Diagnosis

Spirometry (gold standard)

• FEV1/FVC < 0.70 (post-bronchodilator) - confirms airflow obstruction
• FEV1 is reduced; FVC is normal or near-normal
• Obstruction is not fully reversible (unlike asthma)

GOLD Severity Classification (based on FEV1 % predicted)

Clinical Features

• Dyspnea (progressive, especially on exertion)
• Chronic cough with sputum production
• Wheezing and chest tightness
• Barrel chest (increased AP diameter due to hyperinflation)
• Decreased breath sounds, prolonged expiratory phase
• Cyanosis in advanced chronic bronchitis

ABG Findings (classic case - (Costanzo Physiology))

• PaO2 ↓ (e.g., 60 mmHg)
• PaCO2 may be ↓ (if hyperventilating) or ↑ (in severe disease)
• Elevated A-a gradient due to V/Q mismatch

Treatment

Stable COPD (Katzung's Basic and Clinical Pharmacology)

• LAMA (e.g., tiotropium) is often preferred over LABA as first-line for stable COPD
• ICS use is cautious in COPD - less effective than in asthma, and associated with increased risk of bacterial pneumonia
• ICS recommended when: severe airflow obstruction, prior exacerbations, blood eosinophils are high (biomarker-guided)
• Theophylline: no longer routinely recommended (failed to show benefit in large RCT)
• Roflumilast (selective PDE4 inhibitor): approved for COPD, improves FEV1 and reduces exacerbation frequency

• Smoking cessation (most important intervention to slow decline)
• Pulmonary rehabilitation
• Long-term oxygen therapy (LTOT) when PaO2 ≤ 55 mmHg or SpO2 ≤ 88%
• Influenza and pneumococcal vaccination

Acute Exacerbations of COPD (AECOPD)

• Viral respiratory infections (most common)
• Bacterial infections (H. influenzae, S. pneumoniae, M. catarrhalis)
• Air pollution

COPD vs. Asthma - Key Differences

Complications

• Cor pulmonale - right heart failure from pulmonary hypertension
• Polycythemia - from chronic hypoxemia
• Respiratory failure - hypercapnic type II
• Spontaneous pneumothorax - from bullae rupture
• Lung cancer - markedly elevated risk in smokers with COPD

Biomarker-Guided ICS Treatment Strategies in COPD

The Core Concept: Why Biomarkers?

"The blood eosinophil count is a potentially useful prognostic and theragnostic biomarker in COPD. Thresholds, rather than specific target blood eosinophil counts, are associated with beneficial effect." (Fishman's Pulmonary Diseases and Disorders)

Primary Biomarker: Blood Eosinophil Count (BEC)

GOLD 2025 Follow-Up Treatment Algorithm (Eosinophil-Guided)

• For dyspnea-dominant disease: Eosinophils do not guide ICS use - step up from LABA/LAMA regardless
• For exacerbation-dominant disease:
  • BEC < 100: Step up to LABA + LAMA only (ICS not recommended)
  • BEC 100-299: Step up to LABA + LAMA + ICS if ≥2 exacerbations or hospitalization
  • BEC ≥ 300: Step up directly to triple therapy (LABA + LAMA + ICS)
• If still on LABA + LAMA + ICS and exacerbating:
  • Add Roflumilast if FEV1 <50% + chronic bronchitis
  • Add Azithromycin (preferentially in former smokers)
  • Add Dupilumab if BEC ≥300 with chronic bronchitis

ICS Initiation - Key Rules

Initial Treatment (GOLD Groups A/B/E)

• Group A (low symptoms, low exacerbation risk): Start with a bronchodilator; ICS not indicated
• Group B (high symptoms, low exacerbation risk): Start with LABA or LAMA; ICS not routinely indicated
• Group E (high exacerbation risk): LABA + LAMA first-line; add ICS only if BEC ≥300 cells/µL

ICS De-escalation (Withdrawal)

• ICS withdrawal is safe and feasible when long-acting bronchodilators are maintained
• No consistent difference in exacerbation frequency or FEV1 decline between withdrawal and continuation arms
• Caveat: ICS withdrawal in patients with BEC ≥300 cells/µL is associated with a higher risk of exacerbations - de-escalation should be done cautiously in this group

• Development of pneumonia
• Other significant ICS side effects (osteoporosis, hyperglycemia, adrenal suppression)
• BEC persistently < 100 cells/µL (suggests minimal T2 inflammation)
• Widespread ICS prescribing outside guidelines (most common reason)

Triple Therapy and the 100-299 "Gray Zone"

• Triple therapy (budesonide/glycopyrronium/formoterol - BGF) reduced moderate/severe exacerbation rates by 47-56% vs. dual LABA+LAMA
• FEV1 improvement of 62-73 mL favoring BGF
• Benefit seen even without prior exacerbation history and in moderate COPD

Emerging Biomarkers: Beyond Eosinophils

ICS Risks That Make Biomarker Guidance Essential

Summary: The Eosinophil Decision Framework

BEC < 100 cells/µL  →  No ICS (risk > benefit)
BEC 100-299 cells/µL →  ICS if ≥2 exacerbations OR hospitalization
                          (consider step-up in gray zone per KRONOS data)
BEC ≥ 300 cells/µL  →  Add ICS; triple therapy preferred
                          ICS withdrawal risky - monitor closely
BEC ≥ 300 + ongoing exacerbations on triple therapy → Consider dupilumab